2 results
Approved WMORecruiting
• To assess the tolerability and safety of the investigational medicinal product
Approved WMOCompleted
Primary Objective:1. To evaluate the efficacy of sonelokimab at 2 different dose levels (120 mg, 240 mg) compared with placebo in the treatment of participants withactive moderate to severe hidradenitis suppurativa.Secondary Objectives:1. To…